Recent Updates
Recently added Catalysts

PF-07275315

Phase 2

Atopic Dermatitis | Small molecule | Immunology |Pfizer, Inc.|Last Updated: May 4, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDDMC
Total Trials1
Total Enrollment340
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05995964A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 RECRUITING 340 — — Aug 22, 2023Mar 8, 2027May 4, 202698 United States, Australia +5
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.
Week 16

EASI75 (≥75% improvement from baseline) at Week 16

Secondary Endpoints
The number and % of participants achieving vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points
Screening through study completion, an average of 36 weeks.
The number and % of participants achieving EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16
All scheduled timepoints other than Week 16, screening through study completion, an average of 36 weeks.
The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points
Screening through study completion, an average of 36 weeks.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Stage 1_PF-07275315EXPERIMENTALStage 1 PF-07275315 Injections over 12 weeks
Stage 1_PF-07264660EXPERIMENTALStage 1 PF-07264660 Injections over 12 weeks
Stage 1_PlaceboEXPERIMENTALStage 1 Placebo Injections over 12 weeks
Stage 2_PF-07275315 _Dose AEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose BEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose CEXPERIMENTALStage 2 PF-07275315 Injections over 12 weeks.
Stage 2_PF-07275315 _Dose DEXPERIMENTALStage 2 PF-07275315 or PF-07264660 Injections over 12 weeks.
Stage 2_PlaceboEXPERIMENTALStage 2 Placebo Injections over 12 weeks.
Stage 3_Placebo+PF-07275315_Dose AEXPERIMENTALStage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks.
Stage 3_PF-07275315_Dose BEXPERIMENTALStage 3 PF-07275315 Injections for 32 weeks.
Stage 4_PF-07264660_Dose AEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose BEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PF-07264660_Dose CEXPERIMENTALStage 4 PF-07264660 Injections for 12 weeks
Stage 4_PlaceboEXPERIMENTALStage 2 Placebo Injections for 12 weeks
Interventions
NameTypeDescription
PF-07275315DRUGsubcutaneous injection
PF-07264660DRUGsubcutaneous injection
PlaceboOTHERsubcutaneous injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites98

Inclusion Criteria: Must meet the following AD criteria: 1. Participants aged 18 years or older 2. Clinical diagnosis of chronic atopic dermatitis: 1. for at least 6 months prior to Day 1 with diagnosis confirmed by photograph; 2. Either an inadequate response to treatment with standard of ...

Countries:United StatesAustraliaCanadaChinaGermanyJapanPoland
Unlock Eligibility Criteria
Competitive Landscape -Atopic Dermatitis 82 trials
CompanyTickerTrialsLead PhaseDrugs
Eli Lilly and CompanyLLY6PHASE3Baricitinib, corticosteroid, Lebrikizumab, Corticosteroid
AbbVie, Inc.ABBV10PHASE3Upadacitinib, corticosteroids, Dupilumab, Upadacitinib Dose, Dupilumab Dose
Pfizer Inc.PFE12PHASE3Abrocitinib, PF-08049820, PF-07275315, PF-07264660, Midazolam
Sanofi SA Sponsored ADRSNY13PHASE3Amlitelimab, corticosteroids, tacrolimus or pimecrolimus, calcineurin inhibitors, Dupilumab SAR231893
Regeneron Pharmaceuticals, Inc.REGN4PHASE3Dupilumab, REGN20423, dupilumab
Incyte CorporationINCY3PHASE3Ruxolitinib, Vehicle, TCS
Amgen Inc.AMGN1PHASE3Rocatinlimab
Organon & Co.OGN1PHASE3Tapinarof , 1%, Vehicle
Novartis AG Sponsored ADRNVS2PHASE2GIA632, GHZ339
Apogee Therapeutics, Inc.APGE3PHASE2APG777, APG990, Dupilumab
Johnson & JohnsonJNJ1PHASE2JNJ-95597528
Kymera Therapeutics, Inc.KYMR1PHASE2KT-621
Nektar TherapeuticsNKTR1PHASE2Rezpegaldesleukin
Corvus Pharmaceuticals, Inc.CRVS1PHASE2Soquelitinib
Celldex Therapeutics, Inc.CLDX1PHASE2Barzolvolimab
Evommune, Inc.EVMN1PHASE2EVO756
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
Q32 Bio IncQTTB1PHASE2ADX-914
Turn Therapeutics Inc.TTRX1PHASE2GX-03
Arcutis Biotherapeutics IncARQT1PHASE1ARQ-234
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT05995964primaryCompletionDate: changed
LOWMay 24, 2026NCT05995964studyFirstPostDate: changed